BioXcel Therapeutics Inc   Report issue

For profit Phase 2 Phase 4
Founded: Branford CT United States (2017)

Organization Overview

First Clinical Trial
2019
NCT03910660
First Marketed Drug
2022
dexmedetomidine (precedex)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

BIOXCEL | BioXcel Therapeutics | BioXcel Therapeutics Inc

Active Ingredients

Marketed Drugs (1)

dexmedetomidine (precedex) (2022)

Drugs in Phase 4 Trials (2)

dexmedetomidine (precedex) (16 trials)

lorazepam (ativan) (1 trial)

Drugs in Phase 2 Trials (2)

pembrolizumab (keytruda) (2 trials)

talabostat (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bipolar Disorder (Phase 3)

Carcinoma, Small Cell (Phase 2)

Delirium (Phase 2)

Dementia (Phase 2)

Disease (Phase 3)

Mood Disorders (Phase 3)

Neuroendocrine Tumors (Phase 2)

Pancreatic Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Psychomotor Agitation (Phase 3)

Psychotic Disorders (Phase 3)

Schizophrenia (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Substance Withdrawal Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 4